StemCell Therapy

Arthritis has been one of the most common health conditions in Canada for years, affecting people of all ages with symptoms including joint stiffness and painful inflammation. While there is no known cure, researchers are hoping to find more effective ways to treat and manage arthritis. The Arthritis Society of Canada compiles a list of the top 10 research advances each year, highlighting breakthroughs with promising results. The list for 2020 includes two McGill-led projects supervised by Dr. Hosni Cherif and Dr. Ins Colmegna.

Zombie cells and spinal degradation

Osteoarthritis is one of the most common forms of arthritis worldwide, and is caused by the deterioration of joint cartilagetissues that cushion the ends of bones. Cherif, a postdoctoral fellow in McGills Faculty of Medicine and Health Sciences, led a research project on spinal osteoarthritis.

My research goal is to understand how intervertebral discs and joints degenerate leading to axial osteoarthritis, and the associated chronic pain, Cherif wrote in an email to The McGill Tribune.

In particular, Cherif studied the role of senescent cells, often known as zombie cells, which permanently stop dividing but continue to age and evade death.

Cytokines, also known as cellular signalling molecules, are typically involved in aiding the immune response at a site of inflammation, but the accumulation of these molecules can cause degradation of the spine.

[The] accumulation of senescent cells increases cytokine production and inflammationleading to the development ofintervertebral disc degeneration, Cherif wrote.

Cherifs team identified a synthetic drug, RG-7112, and a natural compound, o-Vanillin, capable of eliminating zombie cells while allowing healthy ones to proliferate. The combination of these molecules has the potential to target inflammation in the spine, thereby reducing the associated chronic pain.

This will lead to better management or the alleviation of persistent pain to improve the quality of life of patients with osteoarthritis, Cherif wrote.

Currently, Cherif is expanding his research in drug discovery to treat spinal osteoarthritis by testing out the signalling pathways of other senotherapeutic agents, molecules that specifically target cellular senescence.

Understanding the mechanism of cellular senescence and disc degradation will facilitate [the] development of novel disease-modifying drugs, Cherif wrote.

The more the better: High dose vaccine protection

Rheumatoid arthritis (RA) is an autoimmune type of arthritis in which the immune response mistakenly targets host cells, causing joint damage and inflammation. This makes patients more vulnerable to the adverse effects of viruses such as influenza.

Colmegna, an assistant professor working in the Division of Rheumatology at the McGill University Health Centre, led a study focussing on the implications of influenza infections in RA patients.

Specifically, Colmegna studied the effect on antibody production of a standard dose of the influenza vaccine versus a high dose in those with RA. Antibodies are molecular markers that recognize and bind to foreign invaders, signalling their presence to the immune system and initiating an immunological response.

The findings of our study indicate that compared with the standard dose influenza vaccine, RA patients who receive the high-dose are two to three times more likely to generate protective antibodies against the influenza virus, Colmegna wrote in an email to The McGill Tribune. This may be associated with a reduced risk of developing influenza.

By increasing the likelihood of generating more antibodies against influenza, the higher dose increases the effectiveness of the bodys response to infection.

This study is the first of its kind to show that it is possible for those with RA to achieve better protection against influenza by using an existing high dose vaccine.

Canadian guidelines recommend that RA patients receive an annual standard dose influenza vaccine, Colmegna wrote. However, many RA patients do not generate protective antibodies post-vaccination [.] With this approach, a larger number of patients with rheumatoid arthritis might be protected against influenza, a disease that in these patients is associated with significant morbidity and mortality.

Colmegna hopes that her research findings will increase the availability of high dose vaccines to better protect RA patients against the influenza virus.

The rest is here:
McGill researchers are shaping the future of arthritis treatment - McGill Tribune

Rheumatoid Arthritis Drugs Market

The global Rheumatoid Arthritis Drugs Market report look through various tendencies, obstructions, and challenges faced by the key competitors of Rheumatoid Arthritis Drugs market. The report has been prepared in consideration of the major outcomes and consequences of the market.

Rheumatoid Arthritis Drugs market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Rheumatoid Arthritis Drugs industry comprises of Asia, North America, South America, Middle East and Africa, Europe, with the production and revenue data in each of the sub-segments.The Merck aims at producing XX Rheumatoid Arthritis Drugs in 2020, with XX % production to take place in global market, Novartis accounts for a volume share of XX %.

This report examines the Rheumatoid Arthritis Drugs market status and the potential of global and major regions, from angles of players, product regions and end Application/industries; this report assesses the key players in global and major regions and classifies the Rheumatoid Arthritis Drugs market by product and Application/end industries.

Merck, Novartis, Pfizer, J&J, BMS, Abbvie, Boehringer Ingelheim, AstraZeneca, MedImmune, Takeda, Biogen Idec, Celgene, Bristol-Myers Squibb, Celltrion

HospitalsClinicsHome CareOther

Major Type of Rheumatoid Arthritis Drugs CoveredNSAIDsDMARDsCorticosteroidsAnalgesicsOther

The major objective of this Rheumatoid Arthritis Drugs Industry report is to assist the user get to know the market, understand its definition, segmentation, influential trends, market potential, and the challenges that the market is going through. Profound researches and analysis over the course of the formulation of the report. This report will help the users to understand the market in detail. The facts and the information in respect to the Rheumatoid Arthritis Drugs market are taken from authentic sources as like journals, websites, annual reports of the companies, and others and were reviewed and validated by the industry experts. The data and facts are illustrated in the report using graphs, pie charts, diagrams, and other pictorial representations. This enhances the visual representation and assures understanding the facts in a better way.

The Regional and country-level analysis of the Rheumatoid Arthritis Drugs Market, by end-use.

The Detailed analysis and profiles of additional market players.

About Us:We, Regal Intelligence, aim to change the dynamics of market research backed by quality data. Our analysts validate data with exclusive qualitative and analytics driven intelligence. We meticulously plan our research process and execute in order to explore the potential market for getting insightful details. Our prime focus is to provide reliable data based on public surveys using data analytics techniques. If you have come here, you might be interested in highly reliable data driven market insights for your product/service,reach us here 24/7.

Mention your Queries here to Get a Call from Our Industry Expert @sales@regalintelligence.com

Contact Us:Regal Intelligence: http://www.regalintelligence.comPhone no: +1 231 930 2779 (U.S.) | +44 141 628 8787 (UK)

View original post here:
Rheumatoid Arthritis Drugs Market Comprehensive Growth: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2026 KSU | The...

There's no silver bullet to living longer, says Dan Buettner, a National Geographic Fellow and journalist who studies the habits of people living in the "Blue Zones," which are the places in the world where people live the longest. The places are: Okinawa, Japan; Sardinia, Italy; Nicoya, Costa Rica; Ikaria, Greece, and Loma Linda, California.

But making small changes to your everyday routine from how you spend your lunch hour to whether you keep in touch with friends can make a big difference in the long run, Buettner tells CNBC Make It.

Especially during the Covid pandemic, as most people's lives have been dramatically changed, here are the top three habits from the Blue Zones that Buettner says are important to start now.

Famous research from Harvard has shown that people who have close relationships live longer than those who are isolated.

"If you're socially disconnected, [or] if you don't have three friends you can count on on a bad day, it shaves about eight years off your life expectancy, compared to somebody who's well connected," Buettner says.

During the pandemic, even video calls can have a positive effect: "If the conversation has emotional content to it, it counts," he says.

"In the pre-Covid days, we would take a lunch break and often go eat with a colleague," he says. Since that's not possible for many people during the pandemic, he suggests a mid-day video call with someone you care about. "Make that part of your daily routine," he says.

Lots of research supports that exercising wards off your risk of disease and death, but you don't need an exercise bike or home gym to reap the benefits.

"People in Blue Zones walk every day and they make it to 100 without all the other gadgetry and pageantry of working out," Buettner says.

People who commute to work and have to walk to a bus or train station have a lower risk of developing cardiovascular issues. If you're working remotely and are more sedentary than usual, take walks around the block that mimic your morning and evening commutes, Buettner says. Leave your sneakers or walking shoes by the front door "to constantly remind you to use them," he says.

Going on walks during the pandemic is an easy way to exercise safely outdoors and also to socialize with someone from outside of your household. Dr. Anthony Fauci has said he powerwalks 3.5 miles a day to de-stress after work.

Studies have shown that walking boosts your creativity, improves your memory and even helps you sleep.

Taking short mid-afternoon naps is common in many of the Blue Zones regions, Buettner says.

"People who report napping at least 20 minutes, five days a week, have about a third lower rate of heart disease than people who just motor through the day," he says.

After a nap, you typically feel sharper and have lower levels of the stress hormone cortisol, Buettner says. Over time, regular nappers also have less inflammation in their bodies, he adds. (Chronic inflammation is associated with several diseases.)

The key to avoiding grogginess is to only nap for 20 minutes, according to the National Sleep Foundation.If you're working from home, squeeze in a power nap during your lunch break it could improve your performance. Studies suggest that short power naps can increase job performance by up to 34% and improve alertness by 54%.

Check out:How the pandemic killed your motivation, and 6 simple ways to get it back, according to science

Don't miss: The best credit cards for building credit of 2021

Here is the original post:
3 easy habits of the worlds longest-living people that can keep you happy and healthy during the pandemic - CNBC

On Thursday, the French nun Sister Andr turned 117 and celebrated with an exceptional feast. A first course of foie gras set the tone for capon with fragrant mushrooms, and was washed down with a hearty glass of red wine.

David Tavella, the communications manager for Andrs care home in Toulon, told the Associated Press that red wine is one of Andrs secrets to longevity. Across the table, red wine, Champagne, and port flowed as Andrs friends toasted in her honor.

The meal concluded a few hours later with Sister Andrs favorite dessert, Baked Alaska. It followed a mass in her honor, led by the local Catholic bishop, and a video call with her great, and great-great, nephews.

At this point, Sister Andr is in line to become the worlds oldest living person. Shes currently Europes oldest and the worlds second oldest, right behind Kane Tanaka, who turned 118 last January.

When asked how shell celebrate her next birthday, Andr replied, I wont be here next year. But dont be perturbed, shes repeated the phrase every birthday for the last ten years, so winemakers better start setting aside their best reds for the next feast.

See the rest here:
117 Year Old French Nun Links Red Wine to Her Longevity - VinePair

When it comes to living a long and healthy life, so much emphasis is put on ones diet. Another factor which can contribute positively to an increased lifespan includes owning a dog. From improving mental health to helping with cardiovascular health, being a dog owner could help boost your longevity. How?

Owning a dog and taking it out for daily walks, acts as a social catalyst for a person.

It helps to promote social connections, conversations and can lead to the development of networks of support.

The connectivity of pets helps a person also feel safer and more loved in their own home.

Owning a dog and getting outdoors more often becomes common practice.

A wealth of research indicates that escaping to a neighbourhood park can lower a person's stress levels, decrease blood pressure and reducetherisk of asthma, allergies, diabetes and cardiovascular disease, whileboostingmental health and increasinglife expectancy.

In another study published in the journal Scientific Reports, spending at least 120 minutes outdoors each week can have a major positive effect on life expectancy and overall health.

The study examined data from nearly 20,000 people in Englandfrom 2014 to 2016, which asked them to record their activities within the past week.

It found that people who spent two hours a week or more outdoors reported being in better health and having a greater sense of well-being than people who didnt get out at all.

Go here to see the original:
How to live longer: A dog helps improve heart health & manages stress to boost longevity - Express

Virtual Tasting with Phil Long of Longevity Wines Categories: Culture and Heritage, Beer, Wine, & Spirits Visit Their Website Pricing info: $30

Ticket Info: https://thewinefeed.com/products/virtual-tasting-with-phil-long-of-longevity-wines

We are thrilled to share two of his wines with you as well as a Q&A session hosted by Angela Thorpe and Taryn Scarborough.

Angela Thorpe works as a public historian by day, amplifying stories around Black history and culture across North Carolina. By night, she is an emerging wine educator with a passion for exploring and sharing how Black people have contributed to the U.S. wine industry over time. She earned her WSET Level 1 in 2020. Her favorite wine is Spanish Tempranillo.

Taryn Scarborough is a Raleigh, NC native who earned her WSET Level 1 in 2019. She has a passion for educating and sharing her joy of wine with others. Taryn works as a project manager in the clinical research industry and loves to travel (pre-COVID) in her spare time. Favorite wine varietal: Sauvignon Blanc

This event is virtual and will be conducted live over Zoom as well as recorded so that participants may revisit the event. Each signup includes 2 full bottles of wine. We hope you will join us!

2019 Longevity - Chardonnay

2018 Longevity - Cabernet Sauvignon

Originally posted here:
Virtual Tasting with Phil Long of Longevity Wines :: Shopping & Retail in North Carolina :: Out and About at WRAL.com - WRAL.com

Winda Wilson celebrated her milestone birthday with a spa day at her senior living facility.

HOUSTON This week Wilda Wilson got a surprise for the ages.

On her 105th birthday, she received a surprise spa day.

Ms. Wilda is an inspiration to all of us," said Abraham Mathew, executive director ofParkway Place.

Wilson's family says Wilda is a doer.

She's been getting things done since 1916. That's when she was born on a farm in Kansas. At that time in history, a brand new Model-T cost a whopping $306 and it was only 22 cents a gallon to fill up.

And if you didn't know, the hamburger bun was invented that year.

A lot has changed over the years.

For decades Wilda was a hairdresser and salon owner. But on this special day, Wilson would be the one in the chair being pampered, getting a scalp massage, styling and a manicure.

"Im glad we could bring a smile to her face today, said Mathew.

Masks were the must-have accessory for Wilson's party, but it didn't cover anyone's happiness. Especially not Wilda's on her big day.

Wilson credits her daily breakfast of five extra crispy pieces of bacon and two pieces of toast smothered in jam to her long life.

Originally posted here:
'An inspiration to all of us': Houston woman turns 105, credits bacon and toast to her longevity - KHOU.com

SportFootballHibsDarren McGregor has long since passed the accepted expiration date on a football career.

Saturday, 13th February 2021, 7:00 am

But, having decided to spice things up, the 35 year-old has proved himself unwilling to be constrained by such arbitrary limitations.

The Hibs defender has had to bide his time this season, regularly restricted to one of the substitute slots as others made the starting berths their own. He managed a few League Cup games as those ahead of him in the pecking order were called away on international duty, but it is only in recent weeks that he has been given the chance to impress on league duty. He has not squandered the opportunity.

He lists several factors but, possibly surprisingly, focuses on the medicinal benefits of turmeric.

It was specifically under Neil Lennon and my knee was giving me all sorts of bother. It was a dull ache and Id tried taking injections or spending a day in and a day out. I dont take any anti-inflammatories but I was advised to take turmeric by the sports science team. Its proven to help with inflammation in your joints. I take them in concentrated form like a tablet and Nathan Ring [physio and Hibs Head of Sports Medicine] has devised a plan along with Colin Clancy, the strength and conditioning coach, which has helped me.

This has maybe been 12-18 months of meticulous work in the background. Trying things and if they dont work trying something else. Now I feel amazing, Im in a sweet spot and I would just like to keep it going.

But, as well addressing his physical predicament, as a team player and mentor, he has also had to consider the bigger picture as he waited to break back into the side.

You have to park your ego and accept that the guys who are playing ahead of you deserve to be in the team. The back three before I came in were doing tremendous and I had to wait for my time.

The gaffer decided to put me in and I think I have taken the opportunity but that is because of a lot of hard work that has been done in the background when no-one was really paying attention. That was in the off chance that I would get an opportunity and I think that has helped me to fit in seamlessly.

The endeavours behind the scenes comprise more than just time on the training pitch or in the gym, it is a lifestyle choice and a willingness to embrace any ideas that could squeeze a bit more out of a body he acknowledges is not getting any younger but remains capable of facilitating his playing ambitions.

Coming into the team for the Rangers game that commanding performance at the heart of the backline, helped the team regain its footing after the Betfred Cup semi-final slip. Retaining his place, he has been part of a winning team ever since.

The Leith side had been heading to Ross County in search of a fourth successive win before a frozen pitch saw that match postponed.

But last weeks important victory over Aberdeen means that they will hold onto third place regardless of results elsewhere. And McGregors strong defensive displays and leadership qualities have contributed to that.

But he admits it wasnt so long ago that he feared time was running out for him and while he concedes that he now treats every game as though it could be his last, he says the turmeric has given him a new lease of life.

You are aware that the clock is ticking and your career is winding down but I can only speak for my own personal feelings and how my body feels. There were times in seasons gone by when i was training some days and not training others just so my body could recover but, this season, touch wood, I have trained every single day and done everything asked of me in the gym.

I just need to keep doing what I'm doing every day and see how long I can go.

As a football player growing up I think you think of 30 as this dreaded age but I think it is definitely changing. Paul Hanlon is 31 now; Paul McGinn is 30.

That gives a combined age of 96 for a back three who have managed two clean sheets in the past three games.

Now, 30 is young. People that dont play the game that are the same age as me, who I maybe went to school with and havent looked after themselves the way I have or done the training Ive done, they maybe put themselves in my shoes and think that at 35 Im definitely past it. But people forget the amount of work we do when we come in here and how meticulous we are with diet etc.

Footballers are definitely getting fitter. Maybe 30-40 years ago, 30 was the age of retirement but I can only be honest. I am training every day and Im sure a lot of the guys will say I do well in training, although some might say I just kick people, and I feel good coming in every day. I still enjoy it.

I'm not at a point when I get up every morning and my body is that sore that I'm thinking I can't be bothered going in. I am appreciating that I am in a hugely privileged position and I want to stay in this position for as long as I can so I am willing to sacrifice whatever needs to be sacrificed for me to keep it going and keep playing for Hibs.

A message from the Editor:

Thank you for reading this article. We're more reliant on your support than ever as the shift in consumer habits brought about by coronavirus impacts our advertisers.

Read more:
Hibs defender Darren McGregor reveals the surprising secret behind his longevity and explains why he is not ready to fade into retirement - The...

The Associated Press| Associated Press

PARIS Question: How does one cram enough candles onto a birthday cake for one of the world's oldest survivors of COVID-19? Answer: With 117 candles, you can't.

A French nun who is believed to be the world's second-oldest person celebrated her 117th birthday in style on Thursday, with multiple treats and well-wishes, cards and flowers to fete her exceptional longevity through two world wars and a recent coronavirus infection.

Sister Andr also got a Mass in her honor and a feast with Champagne, red wine and port. Then came a nap followed by more festivities, including an afternoon snack of baked Alaska, her favorite dessert.

"It made me very, very, very, very happy," the birthday girl said. "Because I met all those I love and I thank the heavens for giving them to me. I thank God for the trouble they went to."

Sister Andr's big day got rolling with a morning video call with her great-nephews and great-great nephews, followed by a Mass in her honor led by the local Catholic bishop, said David Tavella, the communications manager for the care home in the southern French city of Toulon where the nun lives.

Her birthday feast included a starter of foie gras, followed by capon with fragrant mushrooms. "All of it washed down with red wine, because she drinks red wine. It's one of her secrets of longevity," Tavella told The Associated Press. There was also port and Champagne "because 117 years have to be toasted," he said.

She skipped dessert because she was tired, but got it served to her later after a nap with three candles and the numerals 117 on top.

Packing on 117 candles would have been impossible.

"We stopped trying a long time ago," Tavella said. "Even if we made big cakes, I'm not sure that she would have enough breath to blow them all out. You would need a fire extinguisher."

Sister Andr's birth name is Lucile Randon. The Gerontology Research Group, which validates details of people thought to be 110 or older, lists her as the second-oldest known living person in the world, behind only an 118-year-old woman in Japan, Kane Tanaka.

Tavella told French media earlier this week that Sister Andr tested positive for the coronavirus in mid-January but she had so few symptoms that she didn't even realize she was infected. Her survival made headlines both in France and beyond.

"When the whole world suddenly started talking about this story, I understood that Sister Andr was a bit like an Olympic flame on a 'round the world tour that people want to grab hold of, because we all need a bit of hope at the moment," Tavella said.

When Tavella talked to her Thursday about celebrating her next birthday in 2022, she replied: "I won't be here next year," he quoted her as saying, adding: "But she has been saying that for 10 years."

By strange coincidence, Tavella celebrated his 43rd birthday on Thursday.

"We often joke that she and I were born on the same day," he said. "I never tell myself that she is 117 because she is so easy to talk to, regardless of age. It is only when she talks about World War I as though she lived through it that I realize, 'Yes, she did live through it!'"

Originally posted here:
COVID-defying nun toasts 117th birthday with wine and prayer - The Topeka Capital-Journal

Global Longevity and Anti-senescence Therapy Market Trends and Forecast

The global longevity and anti-senescence therapies market should grow from $329.8 million in 2018 to $644.4 million by 2023 with a compound annual growth rate (CAGR) of 14.3% during 2018-2023.

Report Scope:

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023.

The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies,.

Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.

The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.

Get Exclusive PDF Sample Copy of This Report:www.trendsmarketresearch.com/report/sample/11698

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.

- 71 data tables and 40 additional tables- An overview of the global longevity and anti-senescence therapy market- Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023- Country specific data and analysis for the United States, Canada, Japan, China, India, U.K., France, Germany, Spain, Australia, Middle East and Africa- Detailed description of various anti-senescence therapies, such as senolytic drug therapy, gene therapy, immunotherapy and other stem cell therapies, and their influence in slowing down aging or reverse aging process- Coverage of various therapeutic drugs, devices and technologies and information on compounds used for the development of anti-ageing therapeutics- A look at the clinical trials and expected launch of anti-senescence products- Detailed profiles of the market leading companies and potential entrants in the global longevity and anti-senescence therapy market, including AgeX Therapeutics, CohBar Inc., PowerVision Inc., T.A. Sciences and Unity Biotechnology

Summary

Global longevity and anti-senescence therapy market deals in the adoption of different therapies and treatment options used to extend human longevity and lifespan. Human longevity is typically used to describe the length of an individuals lifetime and is sometimes used as a synonym for life expectancy in the demography.

Anti-senescence is the process by which cells stop dividing irreversibly and enter a stage of permanent growth arrest, eliminating cell death. Anti-senescence therapy is used in the treatment of senescence induced through unrepaired DNA damage or other cellular stresses.

Get a full access overview AccessNow:www.trendsmarketresearch.com/checkou698/Single

Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and an increasing demand for cell-based assays in research and development.

An increasing geriatric population across the globe and a rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).

According to the National Institutes of Health (NIH), the total geriatric population across the globe in 2016 was over REDACTED. By 2022, the global geriatric population (65 years and above) is anticipated to reach over REDACTED.

An increasing geriatric population across the globe will generate huge growth prospectus to the market.

Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics,.

are working extensively in this field for the extension of human longevity by focusing on study of genomics, microbiome, bioinformatics and stem cell therapies,. These factors are poised to drive market growth over the forecast period.

Global longevity and anti-senescence market is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach REDACTED, registering REDACTED in growth from REDACTED in 2018.

Grab Your Report! Please click here:www.trendsmarketresearch.com/report/ount/11698

The report provides analysis based on each market segment including therapies and application. The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy and Others.

Senolytic drug therapy held the largest market revenue share of REDACTED in 2017. By 2023, total revenue from senolytic drug therapy is expected to reach REDACTED.

Gene therapy segment is estimated to rise at the highest CAGR of REDACTED till 2023. The fastest growth of the gene therapy segment is due to the Large investments in genomics.

For Instance; The National Human Genome Research Institute (U.S.) had a budget grant of REDACTED for REDACTED research projects in 2015, thus increasing funding to REDACTED for approximately REDACTED projects in 2016.

This email address is being protected from spambots. You need JavaScript enabled to view it.

For more information:

Read the rest here:
Global Longevity and Anti-senescence Therapy Market Trends and Forecast interpreted by a new report - WhaTech

Former India batsman, VVS Laxman reveals that he was impressed by Ishant Sharmas will to bowl long spells when he first met the pacer. Laxman lavishes praises on the hard work the Ishant has done since making his debut in 2007 to pick 300 Test match wickets.

On Monday, in Chennai, against England with the wicket of Dan Lawrence, Ishant became the 6th Indian bowler and only the third Indian pacer after Kapil Dev and Zaheer Khan to bag 300 Test wickets.

The lanky seamer has had a career marred with injuries, however, illustrious with some scintillating spells over the years as he reached this feat in his 98th Test. It is often talked about how captains, in domestic cricket and for the national team, have a liking for Ishant because of his endurance to bowl longer spells.

When I was tweeting about his 300th wicket, I remembered the debut Test match of Ishant in 2007 against Bangladesh. A tall, lanky fast-bowler. We all knew he had the talent to do well for India. But the amount of hard work he exhibited throughout his career.

There was Zaheer and other talented fast bowlers like RP Singh, Sreesanth, or Irfan Pathan, but here was one fast bowler who was ready and prepared to bowl 20 overs every day not every innings but every day. Theres a reason why he has had this longevity, VVS Laxman told Star Sports.

VVS Laxman observed that Ishant has a better wrist position and is bowling more fuller lengths than he used to prior to the time spend with former Australia pacer, Jason Gillespie. After remaining unsold in the IPL auction, Ishant went to England to play county cricket for Sussex in 2018 where he was coached by Gillespie.

VVS Laxman reckons the senior India pacer returned a much better and improved bowler from his stint in the county. And rightly so; since the start of 2018, he has picked 74 wickets in 19 Tests at an average of 19.39; compared to the average of 36.55 in his previous 79 Tests.

What changed since 2018, is his wrist position. He is a very hard-working bowler, always looking to improve. He went to Sussex, worked with Jason Gillespie, played in the country championship, and was working on his seam position. And this is what he got right. Since then, he is pitching the ball up and he is ending up getting more wickets, Laxman added.

Also Read: Had Kuldeep Yadav Played For Some Other Country, He Would Have Taken 200 Wickets And Played 50 Tests By Now, Says His Coach Kapil Pandey

Link:
Ishant Sharma Was Prepared To Bowl 20 Overs A Day, That's The Reason For His Longevity - VVS Laxman - Cricket Addictor

Jack and Rose, Allie and Noah, Johnny and Baby, Sandy and Danny these are just some of the most iconic movie couples that spring to mind when we think of L-O-V-E.

For us romantics, its a brief snapshot of a couples unwavering passion for each other that we can escape in for an hour or two (whether thats proving their love by building a house, ensuring nobody puts their beloved in the corner, or letting the other hog the door so they could survive a treacherous icy ocean).

But heres the thing; theres more to relationships than the honeymoon period. And none of our favourite romantic films ever seem to show those uneventful days that come later. You know, like the ones weve endured ourselves in lockdown purgatory, as we constantly ask our partner how their day was, despite fully knowing that it was, quite literally, the same as yesterday.

But no matter how unrealistic we know it is, we cant help but fall back on those same tried-and-tested romcoms.

They play to our longings and desires for connection, says psychologist, author and founder of The Village, Dr Kalanit Ben-Ari.

They are also something we can all relate to so many people are in love with the idea of a romantic relationship. When we are touched by a scenario in a film, we are actually in touch with a part in ourselves. It could be our dreams and longing or fears and losses, which might be in our awareness or unconsciously.

Hoping for a happily ever after certainly isnt a bad thing, but I know my own favourite on-screen couples have skewed my own expectations of love and not exactly in a healthy way.

Im not alone in this, either; as Dr Ben-Ari says: Even though a film can generate feelings of positivity, some might experience an after-effect depending on whats going on in their own life.

For example, a couple at the start of a relationship might be left feeling incredibly positive, whereas couples in an uncertain stage of their relationship might feel a sense of longing and sadness for the disparity between the films story and their reality.

Working closely with Dr Ben-Ari, then, I decided to take a look back at some of those iconic Hollywood couples who many perceive to be epic examples of love.

Some definitely stand the test of time. Others, on closer inspection, have some issues.

Jack and Rose, Titanic

Those of us who have seen Titanic enough times will argue there was space for Jack on that floating door. Which means he sacrificed himself unnecessarily for a holiday romance that had lasted just two days.

Thats right; from the very moment that Jack saved Rose from jumping off the Titanic to the moment he freezes in the Atlantic Ocean, only a little over 48 hours has passed. Anyone else think it was already over for Rose?

Longevity rating: 1/5

Johnny and Baby, Dirty Dancing

Johnny and Baby are from different walks of life who find themselves in the same place at the right time in Dirty Dancing. But, with a considerable age gap between them (and not much in common other than their dancing skills), its likely this love was never built to last outside of Kellermans.

Longevity rating: 2/5

Sandy and Danny, Grease

Shes the ultimate good girl, and hes the bad boy who just wants to get friendly down in the sand. Essentially, Sandy and Danny are complete polar opposites who spend the entire film trying to awkwardly impress each other and their peers.

These typical narratives often carry a deeper meaning to what we see on the surface, says Dr Ben-Ari.

There are unconscious processes or agendas that cause opposites to attract for example, and those who are being pursued might not show any interest as a form of defence mechanism from past pain.

Longevity rating: 2/5

Annette and Sebastian, Cruel Intentions

Yes, its another good girl/bad boy trope.

In Cruel Intentions, Sebastian makes a bet with his scheming stepsister Katherine and winds up falling truly in love with his pure-as-a-dove prey, Annette. When his toxic masculinity finally gives way to vulnerability, though, its too late and we wind up speeding towards the films tragic conclusion.

Longevity rating: 2/5

Josh and Cher, Clueless

Clueless is a full-on Monet: it all looks great from far away but up close-up its a mess. Personally, I swoon over any film with the ageless Paul Rudd, but when Chers true love ends up being his character her eye-rolling, nit-picking stepbrother, Josh it really is a case of as if!

Longevity rating: 2/5

Allie and Noah, The Notebook

Communication is a big deal in a relationship; if you dont tell the other what youre thinking or how youre feeling, then how on earth are they supposed to know?

Noah and Allies short-lived summer romance (which begins, as youll no doubt remember, with him blackmailing her into dating him) is heartbreakingly dragged out through the course of their entire lives, and all because neither of them could be bothered to sit down and have a proper conversation.

Longevity rating: 3/5

Lara Jean and PeterKavinsky, To All the Boys Ive Loved Before

Shes the sweet outsider, hes the cute popular jock: its a familiar story. Unlike Grease and The Notebook, though, these two dont just take the time to get to know one another; they make sure they share the same core moral values, too.

Better still? Even in these modern social media times, its an adorable love letter from Lara Jean to Peter Kavinsky that brings them together. Perfection.

Longevity rating: 4/5

Rosemary and Dill, Easy A

Stanley Tucci and Patricia Clarkson play parents Rosemary and Dill in the classic 2010 film Easy A. They are, quite literally, the backbone of this delightful tale, and they show that mature love can be fun, caring and passionate even while dealing with their daughter Olives slut-shaming drama.

Longevity rating: 5/5

Monica and Quincy, Love And Basketball

Love And Basketball is a cult classic, with childhood sweethearts Monica and Quincy sharing an everlasting bond over the sport. A friendship turns into real love. And, yes, they make some mistakes along the way before finding the right time to be together.

But, as director Gina Prince-Bythewood explains to Shadow And Act about the films iconic sex scene, the whole thing is hinged on the couplds respect for one another.

When we did it, I was very specific about what I wanted it to be, she said. Its a girls first time, Monicas first time, I wanted it to be the fantasyI kind of wanted to give a blueprint for boys and girls of what to expect. I wanted the reality of it. Sanaa [Lathan] and Omar [Epps] were so dope in that scene, so protective of each other. They just gave the realness, especially just the looks that they were giving each other that said so much, which added organic humor to it which I loved.

Lets just ignore that he was two weeks away from the wedding when Monica finally made her move, yeah?

Longevity rating: 4/5

Jim and Michelle, American Pie

Jim loses his virginity to Michelle after prom. She isnt the porn star of his dreams, but shes quirky, and human, and believable. And, while they may seem mismatched, theyre destined to make it down the altar. Band geek and goofball for the win!

Longevity rating: 5/5

Sarah and Derek, Save The Last Dance

When white ballet dancer Sarah ends up at a majority-Black high school, she meets Derek. The interracial couple go against the grain, much to the distaste of his friends and family, but cringeworthy hip hop dancing scenes aside (Lets put that S-E-X in those H-I-P-S) they support each others dreams 100% and find love together.

Longevity rating: 4/5

Erin and Garrett, Going The Distance

This film made me believe that, if you really love someone, you will spend hours talking on the phone to keep that long distance relationship going. Im here, fresh from heartbreak, to tell you that isnt the case. Going The Distance deals with the idea that you cant physically touch someone else for months on end. And, while Erin and Garrett nearly dont make it, after a time jump, a sensible cooling-off period, and a decision to relocate, true love wins.

Longevity rating: 4.5/5

More here:
Best film couples & movie relationships, according to a therapist - Stylist Magazine

YORBA LINDA, Calif., Feb. 8, 2021 /PRNewswire/ -- Dental professionals have long sought improvements in dental implant bridge stability, longevity, and esthetics. NobelProcera Zirconia Implant Bridge is a premium solution that provides individualized, high-end, implant-based restorations and services that seek to improve patient outcomes, esthetics, and implant longevity.

"Precision is a key feature for positive patient outcomes and implant longevity. The NobelProcera Zirconia Implant Bridge is cement-free, manufactured with high-strength material and is an excellent choice," said Prof. Dr. Markus B. Blatz from Philadelphia, Pennsylvania.

Made for estheticsAvailable in 10 precisely matched VITA shades, the NobelProcera Zirconia Implant Bridge is designed with esthetics in mind. It was designed for a smaller, angulated screw channel, with the new Omnigrip Mini Screwdriver to improve occlusal esthetics.

With the recent partnership with DOCERAM Medical Ceramics, the zirconia implant bridges are produced with the high-end Nacera Pearl zirconia material, which meets Nobel Biocare's highest quality standards.

Complete design flexibilityThe new offering is available in full-contour, cut-back, thimble, and framework styles (with or without soft tissue), making it possible to achieve natural looking restorations. The combination of the angulated multi-unit abutment and angulated screw channel provides up to 55 degrees of restorative freedom.

Cement-freeRemoving cement from the equation saves time and simplifies the process of implant bridge procedures.

High precision and material strengthNobelProcera works to achieve the goals of improved stability, durability, and esthetics through a manufacturing process that prioritizes high material strength and superior precision.

NobelProcera Zirconia Implant Bridge is now available in DTX Studio Lab and 3Shape systems.

_________________________Nobel Biocare is a world leader in the field of innovative implant-based dental restorations. The company's portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive and NobelParallel), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera), digital solutions for treatment planning (DTX Studio suite) and guided surgery, as well as biomaterials (creos regenerative solutions). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials.

View original content to download multimedia:http://www.prnewswire.com/news-releases/the-new-nobelprocera-zirconia-implant-bridge-simplifies-the-partnership-between-clinicians-and-technicians-301223356.html

SOURCE Nobel Biocare Usa, Inc.

Company Codes: Swiss:NOBN

More:
The new NobelProcera Zirconia Implant Bridge simplifies the partnership between clinicians and technicians - BioSpace

For centuries many have searched for the secret to a longer life. From not smoking to reducing alcohol intake, there are many ways to help lengthen ones life. Drinking more tea is another healthy approach and in particular Rooibos tea which helps reduce cancer risk, promote healthy hearts and weight loss and boosting longevity.

Rooibos teas health benefits include supporting a healthy heart, preventing cancer, managing and preventing diabetes, supporting healthy digestion, fighting inflammation, promoting stronger bones, supporting weight loss, slowing down ageing process, treating blood pressure, supporting healthy skin, fighting dandruff and supporting kidney health.

The College of Korean medicine conducted a study and found that Rooibos tea has a positive effect on heart health as it helps keep hormone levels balanced and inhibits the release of excessive hormones from the adrenal gland.

This further helps to prevent hypertension and high blood pressure.

Rooibos tea contains nothofagin and aspalathin, which are powerful chemical compounds known to calm inflammation in the vascular system and acts as a vasodilator.

READ MORE-Apple cider vinegar cleaning hacks: 10 household uses for ACV

Rooibos is associated with health benefits due to its high levels of health-promoting antioxidants, which include aspalathin and quercetin.

Antioxidants may help protect cells from damage by free radicals.

In a study published in the US National Library of Medicine National Institutes of Health, free radicals, antioxidants and how it helps with overall health was investigated.

The study noted: When an overload of free radicals cannot gradually be destroyed, their accumulation in the body generates a phenomenon called oxidative stress.

This process plays a major part in the development of chronic and degenerative illness such as cancer, autoimmune disorders, aging, cataract, rheumatoid arthritis, cardiovascular and neurodegenerative diseases.

The human body has several mechanisms to counteract oxidative stress by producing antioxidants, which are either naturally produced in situ, or externally supplied through foods and/or supplements.

Tea chemist and scientist Dr Tim Bond said: There is also evidence to show that rooibos helps protect body cells from oxidative damage.

The explanation for these effects is that rooibos tea contains a diverse range of phenolics including two unique polyphenols, aspalathin and nothofagin, which have a particularly strong anti-oxidative activity.

Rooibos tea also contains essential bone strengthening minerals including potassium, calcium and magnesium all integral for proper bone health.

Rooibos tea could also help to reduce the likelihood of brain function decline.

Follow this link:
How to live longer: Rooibos tea prevents cancer and promotes healthy hearts - Express

Stem Cell Therapy involves the use of stem cells to treat different diseases. These are non-differentiated cells of a multicellular organism. All the cells in the body are specialized for a specific function but they are the only cells without an assigned function. They can differentiate into any type of cell as and when required by the body and can proliferate rapidly to produce multiple copies of a specific type. Sources of stem cells are embryos and adult body tissues. In the adults, stem cells are present in bone marrow, brain, liver, skin, skeletal muscles, blood and blood vessels. While embryonic stem cells are derived from a blastocyst. Nowadays, the Umbilical cord is being stored under suitable conditions to get stem cells from it if needed. This is useful as chances of transplant rejection are less because stem cells are derived from your own umbilical cord.

Bone Marrow Transplant is the most commonly used method to treat various types of cancers such as lymphoma, multiple myeloma, and leukemia, etc. through stem cells. It is also used to treat brain diseases, cardiovascular diseases and cell deficiencies such as diabetes mellitus. Recently, anti-aging stem cell treatments have gain fame. It is used to restore your youth and beauty.

Read the original post:
10 Best Clinics for Stem Cell Therapy in Thailand [2021 ...

ELK CITY, Idaho, Feb.10, 2021 /PRNewswire/ --Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today acquisition of the JadiCell, cell therapy, for use in the treatment of acute respiratory distress syndrome and other lung pathologies.

"Having worked with the Team at Therapeutic Solutions International for over 4 years, I am glad to place our highly promising and clinically advanced stem cell therapy into this innovative and cutting-edge company," said Dr. Amit Patel, inventor of the JadiCell. "Therapeutic Solutions International is unique in that it is currently running clinical trials in the area of nutraceuticals, as well as developing preclinical and clinical stage immunotherapies. There are numerous synergies to be had with the existing work and expertise in the Company."

"While there is a lot of excitement about various approaches to lung inflammation, there are very few therapies that not only potently block pathological immunity while concurrently induce regeneration of pulmonary tissues," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "To date, by far the most promising regenerative therapy our scientists have worked with for acute respiratory distress syndrome (ARDS) has been the JadiCell. I am honored to work with our team of experts such as Dr. Francesco Marincola and Dr. Santosh Kesari in leading the JadiCell through Phase III and into the hands of patients."

"It is a significant accomplishment to acquire rights to this extremely promising and cost-effective technology that is scalable and functions as a 'cellular drug,'" said Famela Ramos, Vice President of Business Development. "To our knowledge this is the only stem cell therapy for lung pathologies that does not require animal components and can be generated in sufficient quantities to address the multi-billion-dollar market of ARDS."

"Dr. Patel and his team have been strong collaborators with us since our first licensing deal using the JadiCell for Chronic Traumatic Encephalopathy," stated Timothy Dixon, President and CEO of the Company. "Having worked with these cells, we appreciate that to date they are by far the most effective at production of cytokines, stimulation of regeneration, and inhibition of pathological inflammation. We are extremely confident in our ability to take these cells to the finish line in treatment of end stage lung disease."

About Therapeutic Solutions International, Inc.Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is http://www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

[emailprotected]

SOURCE Therapeutic Solutions International

Home

The rest is here:
Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung...

Dublin, Feb. 09, 2021 (GLOBE NEWSWIRE) -- The "Cell Therapy Market by Cell Type, Therapy Type, Therapeutic Area, and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The global cell therapy market accounted for $7,754. 89 million in 2019, and is expected to reach $48,115. 40 million by 2027, registering a CAGR of 25. 6% from 2020 to 2027.

Cell therapy involves administration of somatic cell preparations for treatment of diseases or traumatic damages. Cell therapy aims to introduce new, healthy cells into a patient's body to replace diseased or missing ones.

This is attributed to the fact that specialized cells, such as brain cells, are difficult to obtain from human body. In addition, specialized cells typically have a limited ability to multiply, making it difficult to produce sufficient number of cells required for certain cell therapies. Some of these issues can be overcome through the use of stem cells. In addition, cells such as blood and bone marrow cells, mature, immature & solid tissue cells, adult stem cells, and embryonic stem cells are widely used in cell therapy procedures.

Moreover, transplanted cells including induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs) are divided broadly into two main groups including autologous cells and non-autologous cells. Development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. Furthermore, automation in adult stem cells and cord blood processing and storage are the key technological advancements that fuel growth of the market for cell therapy.

In addition, growth in aging patient population, The rise in cell therapy transplantations globally, and surge in disease awareness drive growth of the global cell therapy market. Furthermore, The rise in adoption of human cells over animal cells for cell therapeutics research, technological advancements in field of cell therapy, and increase in incidences of diseases such as cancer, cardiac abnormalities, and organ failure are the key factors that drive growth of the global market.

Moreover, implementation of stringent government regulations regarding the use of cell therapy is anticipated to restrict growth of the market. On the contrary, surge in number of regulations to promote stem cell therapy and increase in funds for research in developing countries are expected to offer lucrative opportunities to the market in the future.

The global cell therapy market is categorized on the basis of therapy type, therapeutic area, cell type, end user, and region. On the basis of therapy type, the market is segregated into autologous and allogenic. By therapeutics, it is classified into malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others.

The global cell therapy market is categorized on the basis of therapy type, therapeutic, cell type, end user and region. On the basis of therapy type, the market is segregated into autologous and allogenic. By therapeutic area, it is classified into malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others. On the basis of cell type, it is segregated into stem cell therapy and non-stem cell type. On the basis of end user, it is segregated into hospital & clinics and academic & research institutes. On the basis of region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

Story continues

The study provides an in-depth analysis of the global cell therapy market along with the current trends and future estimations to elucidate the imminent investment pockets.

Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.

Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.

Extensive analysis of the key segments of the industry helps in understanding the forms and types of cell therapy used across the globe.

Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

Key Topics Covered:

Chapter 1: Introduction1.1. Report Description1.2. Key Benefits for Stakeholders1.3. Key Market Segments1.4. Research Methodology1.4.1. Secondary Research1.4.2. Primary Research1.4.3. Analyst Tools & Models

Chapter 2: Executive Summary2.1. Key Findings of the Study2.2. Cxo Perspective

Chapter 3: Market Overview3.1. Market Definition and Scope3.2. Key Findings3.2.1. Top Player Positioning3.2.2. Top Investment Pockets3.2.3. Top Winning Strategies3.3. Porter'S Five Forces Analysis3.4. Impact Analysis3.4.1. Drivers3.4.1.1. Technological Advancements in the Field of Cell Therapy3.4.1.2. The Rise in Number of Cell Therapy Clinical Studies3.4.1.3. The Rise in Adoption of Regenerative Medicine3.4.2. Restraint3.4.2.1. Developing Stage and Pricing3.4.3. Opportunity3.4.3.1. High Growth Potential in Emerging Markets3.5. Impact of Covid-19 on Cell Therapy Market

Chapter 4: Cell Therapy Market, by Cell Type4.1. Overview4.1.1. Market Size and Forecast4.2. Stem Cell4.2.1. Key Market Trends and Opportunities4.2.2. Market Size and Forecast, by Region4.2.3. Market Size and Forecast, by Type4.2.3.1. Bone Marrow, Market Size and Forecast4.2.3.2. Blood, Market Size and Forecast4.2.3.3. Umbilical Cord-Derived, Market Size and Forecast4.2.3.4. Adipose-Derived Stem Cell, Market Size and Forecast4.2.3.5. Others (Placenta, and Nonspecific Cells), Market Size and Forecast4.3. Non-Stem Cell4.3.1. Key Market Trends and Opportunities4.3.2. Market Size and Forecast, by Region

Chapter 5: Cell Therapy Market, by Therapy Type5.1. Overview5.1.1. Market Size and Forecast5.2. Autologous5.2.1. Key Market Trends and Opportunities5.2.2. Market Size and Forecast, by Region5.2.3. Market Analysis, by Country5.3. Allogeneic5.3.1. Key Market Trends and Opportunities5.3.2. Market Size and Forecast, by Region5.3.3. Market Analysis, by Country

Chapter 6: Cell Therapy Market, by Therapeutic Area6.1. Overview6.1.1. Market Size and Forecast6.2. Malignancies6.2.1. Market Size and Forecast, by Region6.2.2. Market Analysis, by Country6.3. Musculoskeletal Disorders6.3.1. Market Size and Forecast, by Region6.3.2. Market Analysis, by Country6.4. Autoimmune Disorders6.4.1. Market Size and Forecast, by Region6.4.2. Market Analysis, by Country6.5. Dermatology6.5.1. Market Size and Forecast, by Region6.5.2. Market Analysis, by Country6.6. Others6.6.1. Market Size and Forecast, by Region6.6.2. Market Analysis, by Country

Chapter 7: Cell Therapy Market, by End-user7.1. Overview7.1.1. Market Size and Forecast7.2. Hospitals & Clinics7.2.1. Key Market Trends and Opportunities7.2.2. Market Size and Forecast, by Region7.2.3. Market Analysis, by Country7.3. Academic & Research Institutes7.3.1. Key Market Trends and Opportunities7.3.2. Market Size and Forecast, by Region7.3.3. Market Analysis, by Country

Chapter 8: Cell Therapy Market, by Region8.1. Overview8.2. North America8.3. Europe8.4. Asia-Pacific8.5. LAMEA

Chapter 9: Company Profiles9.1. Allosource9.1.1. Company Overview9.1.2. Company Snapshot9.1.3. Operating Business Segments9.1.4. Product Portfolio9.1.5. Key Strategic Moves and Developments9.2. Cells for Cells9.2.1. Company Overview9.2.2. Company Snapshot9.2.3. Operating Business Segments9.2.4. Product Portfolio9.3. Holostem Terapie Avanzate Srl9.3.1. Company Overview9.3.2. Company Snapshot9.3.3. Operating Business Segments9.3.4. Product Portfolio9.4. Jcr Pharmaceuticals Co. Ltd.9.4.1. Company Overview9.4.2. Company Snapshot9.4.3. Operating Business Segments9.4.4. Product Portfolio9.4.5. Business Performance9.4.6. Key Strategic Moves and Developments9.5. Kolon Tissuegene, Inc.9.5.1. Company Overview9.5.2. Company Snapshot9.5.3. Operating Business Segments9.5.4. Product Portfolio9.5.5. Key Strategic Moves and Developments9.6. Medipost Co. Ltd.9.6.1. Company Overview9.6.2. Company Snapshot9.6.3. Operating Business Segments9.6.4. Product Portfolio9.6.5. Business Performance9.7. Mesoblast Ltd9.7.1. Company Overview9.7.2. Company Snapshot9.7.3. Operating Business Segments9.7.4. Product Portfolio9.7.5. Business Performance9.8. Nuvasive, Inc.9.8.1. Company Overview9.8.2. Company Snapshot9.8.3. Operating Business Segments9.8.4. Product Portfolio9.8.5. Business Performance9.9. Osiris Therapeutics, Inc.9.9.1. Company Overview9.9.2. Company Snapshot9.9.3. Operating Business Segments9.9.4. Product Portfolio9.10. Stemedica Cell Technologies, Inc.9.10.1. Company Overview9.10.2. Company Snapshot9.10.3. Operating Business Segments9.10.4. Product Portfolio

For more information about this report visit https://www.researchandmarkets.com/r/bja7iz

See the rest here:
Outlook on the Cell Therapy Global Market to 2027 - Opportunity Analysis and Industry Forecasts - Yahoo Finance

The global stem cell therapy market is expected to witness a CAGR of 10.6% during the forecast period 2019-2024, and is also anticipated to reach USD 214.5 million by 2024. Growing awareness related to the therapeutic potency of stem cells, development of infrastructure related to stem cell banking and processing, development of advanced genome-based cell analysis techniques, and increasing private-public investment for the development of stem cell therapies are driving the growth of the stem cell therapy market.

Get a free copy of sample report: https://www.vynzresearch.com/healthcare/stem-cell-therapy-market/request-sample

Supportive regulations to drive the growth of the stem cell therapy market

Supporting regulations across developing countries, increasing prevalence of chronic diseases, technological advancement in healthcare, cellular therapies are the major advancements in transforming healthcare and identification of new stem cell lines are also fueling the growth of the stem cell therapy market.

Diseases such as osteoarthritis, multiple sclerosis, heart failure, hearing loss and cerebral palsy are some of the diseases that could be treated using stem cell therapies. For instance, according to the WHO by 2050, it is estimated 900 million people will have disabling hearing loss. Moreover, 60 percent of childhood hearing loss is due to preventable causes.

Allogenic stem cell therapy market to hold the larger share in the market

There are two types of stem cell therapy, allogeneic and autologous. Of both, allogenic segment account for the larger share and is also predicted to grow at the faster rate in the coming years in the market due to its extensive therapeutic applications, increasing commercialization of allogeneic products, easy production scale-up process, and growing number of clinical trials related to allogeneic therapies.

The stem cell therapy market has been segmented by therapeutic application into gastrointestinal diseases, musculoskeletal disorders, surgeries, cardiovascular diseases, and wound and injuries. Musculoskeletal disorders category contributed the largest revenue in the market due to increasing prevalence of musculoskeletal disorders and bone & joint diseases, increasing availability of stem cell-based products for the treatment of musculoskeletal disorders, and growing patient preference for effective & early treatment strategies.

Do you have any specific research requirement? Ask for customization: https://www.vynzresearch.com/healthcare/stem-cell-therapy-market/customize-report

The global stem cell therapy market has also been segmented by cell source into adipose tissue-derived mesenchymal stem cell, cord blood cells and bone marrow-derived mesenchymal stem cells. Of all the categories, the bone marrow-derived mesenchymal stem cells are increasingly being used for therapeutic applications.

North America offers huge opportunities for stem cell therapy industry players

The North American stem cell therapy market will remain the largest during the forecast period. The region is further predicted to observe the fastest growth during the forecast period in the global market owing to technological upgradation and large capital invested in the research and development activities. Moreover, increasing number of clinical trials to evaluate therapeutic potential of products, increasing prevalence of chronic diseases, the growing patient base for target diseases, growing public awareness related to the therapeutic potency of therapy, and increasing public-private funding & research grants for developing safe and effective stem cell therapy products are also supporting the growth of the North American stem cell therapy market.

Investing in research and development is the key strategy adopted by the market players

Major players in the industry are investing in the development of innovative and new products, which is strengthening their position in the stem cell therapy market. In February 2018, MEDIPOST announced that FDA has approved its stem cell-based Alzheimers disease drug, NEUROSTEM for clinical trials. Similarly, in March 2017, Osiris Therapeutics launched Prestige Lyotechnology, a method for storage of living cells and tissues.

Some of the key players operating in the stem cell therapy industry are Osiris Therapeutics, Inc., RTI Surgical, Inc., MEDIPOST Co., Ltd., Nuvasive, Inc., Pharmicell Co., Ltd., Holostem Terapie Avanzate Srl, JCR Pharmaceuticals Co., Ltd., Anterogen Co., Ltd., and Allosource.

More from VynZ Research

Global Stem Cell Banking Market Analysis and Forecast to 2024

The global stem cell banking market is growing at a CAGR of 9.1% during the forecast period reaching USD 10.5 billion by 2024, due to the development of novel technologies of storage, preservation and processing. Stem cell banking is the method of accumulating cord blood, extorting and cryogenically freezing its stem cells for forthcoming use. Cord blood stem cells are used for treating blood diseases such as sickle cell disease, leukemia, and thalassemia. The global stem cell banking market is growing at a significant rate due to the development of novel technologies of storage, preservation and processing. The market has witnessed a high demand for placenta stem cells over the last few years, due to the increasing public awareness regarding the therapeutic prospective of stem cells.

Explore more at: https://www.vynzresearch.com/healthcare/stem-cell-banking-market/request-sample

Global Protein Expression Market Analysis and Forecast to 2024

The global protein expression market was evaluated at USD 1,873.1 million in 2018. The protocol for expression of proteins makes use of expression vectors, competent cells, reagents, instrument, and services. The reagents are the estimated to hold the largest share due to large volume used in the bio-experiments. The significant growth in the protein expression industry is primarily due to the increasing funds from government and non-government organization for protein research, the soaring prevalence of chronic diseases, rising life science industry.

Explore more at: https://www.vynzresearch.com/healthcare/protein-expression-market/request-sample

U.S. Protein Expression Market Analysis and Forecast to 2024

The U.S. protein expression market is expected to grow at a CAGR of 11.6% during the forecast period with its market size predicted to reach USD 1.2 billion by 2024. The U.S. protein expression market is primarily driven by the factors such as the increasing prevalence of chronic diseases, increasing investment for recombinant protein expression, advancement in technology for expression systems, increasing geriatric population, and robust growth of the life sciences industry in the country. Prokaryotic expression systems and mammalian cell expression systems are the major contributors to the protein expression industry in the region.

Explore more at: https://www.vynzresearch.com/healthcare/us-protein-expression-market/request-sample

Contact Us:

VynZ Research

Call: +91-996-028-8381

Toll Free (U.S. and Canada): +1-888-253-3960

Email: enquiry@vynzresearch.com

Connect with Us: LinkedIn | Facebook | Twitter

Go here to see the original:
Global Stem Cell Therapy Market Set to Reach USD 214.5 Million by 2024 - The Courier

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more patients, today announced data presentations across its stem cell mobilization and targeted conditioning programs at the Transplantation and Cellular Therapy (TCT) Annual Meeting, to be held virtually on February 8-12, 2021.

Magenta continues to generate encouraging data across our pipeline, furthering our commitment to patients to expand eligibility and improve the clinical outcomes with stem cell transplant, said John Davis Jr., M.D., M.P.H., M.S., Magentas Head of Research & Development and Chief Medical Officer. Our presentations this year at TCT highlight the potential wide-ranging utility of our portfolio, and we are particularly excited to share these results, and to continue our progress in the year ahead.

Oral Presentations Showcasing Clinical Data of MGTA-145 Stem Cell Mobilization Program

Magenta is developing MGTA-145 in combination with plerixafor utilizing complementary mechanisms to mobilize hematopoietic stem cells (HSCs) for collection and transplantation. This combination has the potential to be the preferred mobilization regimen for rapid, reliable, predictable and safe collection of high numbers of functional blood stem cells to improve outcomes across autologous and allogeneic stem cell transplantation, which also includes stem cells necessary for all HSC-based gene therapies.

Title: MGTA-145 / Plerixafor-Mediated HSC Mobilization and Intravenous HDAd5/35++ Vector Injection into Mice Allows for Efficient in vivo HSC Transduction and Stable Gene Marking in Peripheral Blood Cells (Oral Abstract, #16)Presenting Author: Chang Li, Ph.D., Division of Medical Genetics, Department of Medicine, University of WashingtonDate and Time of Presentation: Session B Transplantation for Non-Malignant Disease; Monday, February 8, 2021, 3:15PM CST / 4:15PM EST

Data from this preclinical study demonstrate the potential of MGTA-145 plus plerixafor to serve as an efficient, single-dose mobilization regimen for in vivo HSC gene therapy where stem cells could be gene corrected or edited without having to remove them from the body. This could potentially replace current mobilization regimens that rely on ex vivo gene therapy approaches to treat genetic diseases.

Title: MGTA-145, in Combination with Plerixafor in a Phase 1 Clinical Study, Mobilizes Large Numbers of Hematopoietic Stem Cells and a Graft with Potent Immunosuppressive Properties for Autologous and Allogeneic Transplant (Oral Abstract, #35)Presenting Author: Kevin Goncalves, Ph.D., Magenta TherapeuticsDate and Time of Presentation: Session E Consider the Source: Stem Cell Grafts and Donors; Tuesday, February 9, 2021, 4:00PM CST / 5:00PM EST

Data from this Phase 1 clinical trial with healthy volunteers further underscore the potential utility of MGTA-145 plus plerixafor as an effective, single-day mobilization and collection regimen for autologous and allogeneic HSC transplant. MGTA-145 plus plerixafor mobilized high numbers of HSCs and showed durable engraftment, successful gene-modification and immunosuppressive properties by reducing Graft-versus-Host disease (GvHD) in preclinical models.

Oral Presentation Showcasing Preclinical Study of MGTA-117 Targeted ADC Conditioning Program

Magenta is developing a suite of novel antibody-drug conjugates (ADCs) for conditioning, a step in the transplant process that currently relies on the use of systemic chemotherapy agents and radiation. Magentas targeted conditioning programs are designed to selectively eliminate stem cells and/or immune cells from a patient prior to transplant or gene therapy, and to reduce or potentially eliminate the need for high dose or high intensity chemotherapy-based treatments. These programs focus on developing targeted products that remove specific cell types, with an approach that is tailored to the patients disease and transplant requirements.

MGTA-117, Magentas most advanced conditioning program, is a CD117-targeted ADC designed to precisely deplete hematopoietic stem and progenitor cells to clear space in the bone marrow prior to transplant, and to support long-term engraftment and improved disease outcomes in patients. MGTA-117 has shown to be highly selective with potent activity, efficacy and tolerability in preclinical models.

Title: A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-life Provides Dual Conditioning and Anti-Leukemia Activity and Extends Survival Compared to Standard of Care in Multiple Pre-clinical Models of Acute Myeloid Leukemia (AML) (Oral Abstract, #53)Presenting Author: Leanne Lanieri, M.S., Magenta TherapeuticsDate and Time of Presentation: Session H Novel Conditioning Regimens & Transplantation for Aged Populations, Wednesday, February 10, 2021, 4:00PM CST / 5:00PM EST

Hematopoietic stem cell transplant (HSCT) can often be a curative treatment for patients with acute myeloid leukemia (AML). There is currently a need for safer and more effective targeted conditioning agents, as current conditioning regimens are associated with severe toxicities and high post-transplant relapse or graft failure. MGTA-117 was studied in multiple human leukemic xenograft murine models to mimic untreated and refractory AML. In preclinical models, MGTA-117 significantly increased median survival versus a multi-day standard-of-care regimen using cytarabine. Data from this study demonstrate MGTA-117s potential as a potent, targeted HSCT conditioning agent with anti-leukemic activity, emphasizing its potential to improve HSCT outcomes in AML by reducing the risk of post-transplant relapse.

Poster Presentation Highlighting Preclinical Data of CD45-ADC Targeted Conditioning Program

Magentas other ADC-based conditioning program, CD45-ADC, targets both patient HSCs and disease-causing immune cells. The programs lead target is CD45, a cell surface molecule broadly expressed throughout the hematopoietic and immune systems. CD45-ADC has the potential to significantly increase the number of patients eligible to receive a stem cell transplant, particularly those patients with autoimmune diseases and acute leukemias.

Developing a broad targeting approach for safer patient conditioning prior to HSCT could bring the curative potential of allogeneic HSCT to more patients with both malignant and non-malignant disorders. Current conditioning regimens limit accessibility of this procedure due to toxicity.

Title: Targeted CD45 Antibody Drug Conjugate Enables Full Mismatch Allogeneic Hematopoietic Stem Cell Transplantation in a Murine HSCT Model as a Single Agent (AML) (Poster #242)Lead Author: Sharon Hyzy, M.S., Magenta Therapeutics

Data from this study showed conditioning with single agent CD45-ADC enabled complete chimerism in a full mismatch allogeneic HSCT model.

Oral Presentation of MGTA-456 Stem Cell Therapy Expansion Program in Patients with Blood Cancer

Magenta is continuing long-term patient follow up to evaluate MGTA-456 in blood cancers through the investigator-initiated Phase 2 trial in blood cancers at the University of Minnesota and will assess best next steps for the program. Magenta previously announced in June 2020 it had discontinued enrollment in the Phase 2 trial of MGTA-456 in patients with inherited metabolic disorders.

Title: MGTA-456, A CD34 Expanded Cord Blood Product, Permits Selection of Better HLA Matched Units and Results in Rapid Hematopoietic Recovery, Uniform Engraftment and Reduced Graft-Versus-Host Disease in Adults with High-Risk Hematologic Malignancies (Oral Abstract, #31)Presenting Author: Heather Stefanski, M.D., Ph.D., Assistant Professor, Department of Pediatrics, University of MinnesotaDate and Time of Oral Presentation: Session E Consider the Source: Stem Cell Grafts and Donors; Tuesday, February 9, 2021, 3:00PM CST / 4:00PM EST

Twenty-two patients were enrolled in the study, with 18 transplanted with MGTA-456. Compared to transplant patients who had undergone the same conditioning, GvHD prophylaxis and supportive care, patients who received MGTA-456 showed faster neutrophil recovery (median of 17 days compared to 23 days) and better platelet recovery (median 36 days compared to 59 days). Additionally, incidence of grade 2-4 acute GvHD was lower (24% compared to 46%), likely because of the ability to find a better matched cord unit.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with blood cancer, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit http://www.magentatx.com.

Follow Magenta on Twitter: @magentatx.

Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Magentas future expectations, plans and prospects, including, without limitation, statements regarding expectations and plans for presenting clinical data, projections regarding our long-term growth, cash, cash equivalents and marketable securities, the anticipated timing of our clinical trials and regulatory filings, the development of our product candidates and advancement of our clinical programs, the timing, progress and success of our collaborations, as well as other statements containing words such as may, will, could, should, expects, intends, plans, anticipates, believes, estimates, predicts, projects, seeks, endeavor, potential, continue or the negative of such words or other similar expressions that can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from pre-clinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities; regulatory approvals to conduct trials or to market products; whether Magenta's cash resources will be sufficient to fund Magenta's foreseeable and unforeseeable operating expenses and capital expenditure requirements; risks, assumptions and uncertainties regarding the impact of the continuing COVID-19 pandemic on Magentas business, operations, strategy, goals and anticipated timelines, Magentas ongoing and planned pre-clinical activities, Magentas ability to initiate, enroll, conduct or complete ongoing and planned clinical trials, Magentas timelines for regulatory submissions and Magentas financial position; and other risks concerning Magenta's programs and operations set forth under the caption Risk Factors in Magentas Annual Report on Form 10-K filed on March 3, 2020, as updated by Magentas most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Go here to see the original:
Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning...

Stem Cell Therapy Market

Stem Cell Therapy Market Projections (2020-2029): The Global market Stem Cell Therapy theologizes is the most recent of the world business market curves. The report prospects the current and frequent collectors, technological innovations, product supplementation, and their representation of performance broadly across the foreign market.

Thisphenomenalstudy on world-widebusiness includes the results of vital primary and secondary resources. These research findings are accepted by the companys skilled analysts and experts, providing rich in-depth information to associated partners, appraisers as well as captains of the industry.

Get a Sample Copy of this Report @ https://www.regalintelligence.com/request-sample/148234

Prominent players in the industry covered in the report:

Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCRPharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix)

Market split by Type, can be divided into:AutologousAllogeneic

Market split by Application, can be divided into:Musculoskeletal DisorderWounds & InjuriesCorneaCardiovascular DiseasesOthers

Market split by Sales Channel, can be divided into:Direct ChannelDistribution Channel

Ourstudypasses through ahaven ofprofound qualitative and quantitativeresearch by industryexperts andprofessionals.Within the reportcontributes a broadperceptionof thepast as well ascurrent marketvista,which implies future statistics and prospects in position with the technical developments over time. Furthermore, the report includes and provides analyses of demand and supply, microeconomic and macroeconomic elements, administrative components and growth indices through the Stem Cell Therapy marketplace. The report outlines keytacticsutilized bykey market participants.

Reach us to quote the effective price of this report (UPTO 50% OFF) @ https://www.regalintelligence.com/check-discount/148234

This report provides an accurate understanding and discovery of key geographic areas underway with market Stem Cell Therapy, including critical segments and additional segments.The report sets out aspects of territorial growth and the size and scope of the market. Additionally, the report also deals with trading information such as business range, cost and revenue margin as well as gross value. However, this understanding assists readers in the conduct of consumer experts as well as major tactic to reach market share.

Substantivebeneficiaries:

Additional Information:

This reportcontributes to the following:

Important questions answered within this report:

About Us:We, Regal Intelligence, aim to change the dynamics of market research backed by quality data. Our analysts validate data with exclusive qualitative and analytics driven intelligence. We meticulously plan our research process and execute in order to explore the potential market for getting insightful details. Our prime focus is to provide reliable data based on public surveys using data analytics techniques. If you have come here, you might be interested in highly reliable data driven market insights for your product/service,reach us here 24/7.

Mention your Queries here to Get a Call from Our Industry Expert @sales@regalintelligence.com

Contact Us:Regal Intelligence: http://www.regalintelligence.comPh no: +1 231 930 2779 (U.S.) | +44 141 628 8787 (UK)

Go here to see the original:
Stem Cell Therapy Market Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast By 2029: Osiris Therapeutics, NuVasive, Chiesi...